# A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction

> **NCT07306182** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Sungen Biomedical Technology Co., Ltd** · enrollment: 210 (estimated)

## Conditions studied

- Anterior Myocardial Infarction

## Interventions

- **DRUG:** SGC001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07306182
- **Lead sponsor:** Beijing Sungen Biomedical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07306182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07306182, "A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07306182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*